http://www.exicuretx.com
Exicure, Inc. Company Intro
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for immuno-oncology, genetic disorders, and other indications. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. Exicure, Inc. has collaboration agreements with Allergan plc; DERMELIX, LLC; and Purdue Pharma L.P. The company was founded in 2011 and is headquartered in Skokie, Illinois.
Industry
Healthcare
Exicure, Inc. Headquaters
8045 Lamon Avenue
Skokie,60077
United States
Exicure, Inc. Share price
17 May 2023 14:08 GMT
$1.0700
-0.0 (-0.26 %)
Exicure, Inc. Market cap
$9.078 M
WMC RANKING
2023
Exicure, Inc. # 150
BiotechnologyLatest Exicure, Inc. News
28 Nov 2023
Press release distribution, EDGAR filing, XBRL, regulatory filings
NEW YORK--( BUSINESS WIRE)--G-III Apparel Group, Ltd. (NASDAQ: GIII) a global leader in fashion with expertise in design, sourcing, and manufacturing,...
28 Nov 2023
Exicure receives Nasdaq delinquency notice on late filing of its form 10-Q (NASDAQ:XCUR)
Exicure (XCUR) receives notice of non-compliance from Nasdaq over late filing of quarterly report, has 60 days to submit a plan for regaining compliance.
WMC Market Score
WMC Market to Revenue Score
Exicure, Inc. Market Financials
Revenue, Expenses, Profit
| Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
| Exicure, Inc. | USD | $8,427 | $46,554 | $-38,295 | $91M | 150 |
| Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $804,390B | 1 |
| Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $878,880B | 2 |
| Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ | 3 |
| Incyte Corporation | USD | $2,702,913 | $2,048,306 | $478,480 | $144,340B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Exicure, Inc. Social Followers vs Top 4 Industry Competitors
Exicure, Inc. Post vs Top 4 Industry Competitors
Exicure, Inc. Digital Footprint By Size vs Top 4 Industry Competitors
Exicure, Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
Exicure, Inc. WMC Market Score Calculations
| Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
| Exicure, Inc. | 0.09 | 0 | 0 | 0 | 0 | 0 | 0 |
| Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 28 | 0 | 0 | 29.94 |
| Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 40 | 0 | 0 | 36.32 |
| Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 32 | 0 | 0 | 100 |
| Incyte Corporation | 29.39 | 5.03 | 0.04 | 100 | 0 | 0 | 45.31 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge
